ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic…